LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Fedratinib | 0.37 | uM | LJP5 | 3 | L04 | 72 | hr | 1476 | 3661 | 3796 | 0.9643 | 0.9473 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 1 | L03 | 72 | hr | 1476 | 2747 | 3788 | 0.7251 | 0.5787 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 2 | L03 | 72 | hr | 1476 | 3324 | 3731 | 0.8909 | 0.8344 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 3 | L03 | 72 | hr | 1476 | 3056 | 3796 | 0.8049 | 0.7055 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 1 | L02 | 72 | hr | 1476 | 2135 | 3788 | 0.5635 | 0.3115 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 2 | L02 | 72 | hr | 1476 | 2415 | 3731 | 0.6472 | 0.4446 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 3 | L02 | 72 | hr | 1476 | 2276 | 3796 | 0.5995 | 0.3738 |
| SK-BR-3 | Fedratinib | 10 | uM | LJP5 | 1 | L01 | 72 | hr | 1476 | 1072 | 3788 | 0.2830 | -0.2099 |
| SK-BR-3 | Fedratinib | 10 | uM | LJP5 | 2 | L01 | 72 | hr | 1476 | 1055 | 3731 | 0.2828 | -0.2224 |
| SK-BR-3 | Fedratinib | 10 | uM | LJP5 | 3 | L01 | 72 | hr | 1476 | 1406 | 3796 | 0.3703 | -0.0354 |
| SK-BR-3 | Trametinib | 0.04 | uM | LJP5 | 1 | P24 | 72 | hr | 1476 | 2426 | 3788 | 0.6403 | 0.4408 |
| SK-BR-3 | Trametinib | 0.04 | uM | LJP5 | 2 | P24 | 72 | hr | 1476 | 2532 | 3731 | 0.6786 | 0.4966 |
| SK-BR-3 | Trametinib | 0.04 | uM | LJP5 | 3 | P24 | 72 | hr | 1476 | 2320 | 3796 | 0.6111 | 0.3932 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 1 | P23 | 72 | hr | 1476 | 2786 | 3788 | 0.7354 | 0.5952 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 2 | P23 | 72 | hr | 1476 | 2810 | 3731 | 0.7531 | 0.6179 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 3 | P23 | 72 | hr | 1476 | 2737 | 3796 | 0.7209 | 0.5729 |
| SK-BR-3 | Trametinib | 0.37 | uM | LJP5 | 1 | P22 | 72 | hr | 1476 | 2517 | 3788 | 0.6644 | 0.4804 |
| SK-BR-3 | Trametinib | 0.37 | uM | LJP5 | 2 | P22 | 72 | hr | 1476 | 2495 | 3731 | 0.6687 | 0.4802 |
| SK-BR-3 | Trametinib | 0.37 | uM | LJP5 | 3 | P22 | 72 | hr | 1476 | 2618 | 3796 | 0.6896 | 0.5224 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 1 | P21 | 72 | hr | 1476 | 2582 | 3788 | 0.6815 | 0.5084 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 2 | P21 | 72 | hr | 1476 | 2713 | 3731 | 0.7271 | 0.5759 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 3 | P21 | 72 | hr | 1476 | 2726 | 3796 | 0.7180 | 0.5683 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 1 | P20 | 72 | hr | 1476 | 2656 | 3788 | 0.7010 | 0.5401 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 2 | P20 | 72 | hr | 1476 | 2604 | 3731 | 0.6979 | 0.5283 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 3 | P20 | 72 | hr | 1476 | 2725 | 3796 | 0.7177 | 0.5679 |